Thirty year ago, Nigerians with End-Stage Renal Disease (ESRD) or kidney failure for short, faced certain death. There was no treatment that could replicate the functions of the kidney which is basically to remove toxins, waste and excess water from the Blood Stream.
In Nigeria like most developing countries many people with ESRD currently go untreated. A recent report revealed that only 50 patients per million received dialysis treatment even though the prevalent rate is as high as 1000 per million primarily because of the huge cost of treatment.
It’s with this in mind that Biomedical Ltd, in 1984 pioneered the local production of Dialysis concentrates (Biolyte) for various Dialysis machines nationwide.
We offered a range of concentrates for acetate and bicarbonate treatment for individually tailored requirement.
1990, in a JOINT VENTURE with the College of Medicine Obafemi Awolowo University (OAU) Ile-Ife, we successfully introduced Peritoneal Dialysis (PD) Fluids which is another treatment option for kidney failure.
BIRTH OF CAPD IN NIGERIA…. another First from Biomedical!!
Biomedical Limited takes great pride in Announcing to the Medical practitioners especially the Nephrology community, Pharmacist, nurses and the general public at large about the debut of our new product-Continuous Ambulatory Peritoneal Dialysis (CAPD) which is used to remove waste products and excess fluids from the blood. Biomedical has introduced CAPD which is a complementary option to the more traditional of Hemodialysis (HD). As a home therapy, CAPD presents lifestyle advantages, allowing patients to work or be at home while administering their therapy. It also does not require a capital-intensive infrastructure (clinics and personnel) making it ideal for use in developing countries such as Nigeria where many people with kidney disease currently go untreated mainly because of the high cost of treatment associated with HD.
This method in short reduces the pressure on hospital services and attention of Doctors and nurses. In the treatment of renal failure.
This Birth of CAPD (1.5% & 2.5%) goes to underscore Biomedical’s long history of being a pioneering company in the critical care management sector of the Nigeria healthcare system.
This is a feat that is borne out of actualizing its vision to be the reference point in production of quality lifesaving pharmaceutical products.
Indeed, as the parent home of intravenous fluids in Nigeria, Biomedical has continued in its stride as a foremost indigenous healthcare solution provider in support of Government’s efforts at bridging the gap in the distribution, availability and access to live-saving drugs and medical consumables.
We cannot fail to acknowledge the significant role played by the National Association of Nephrologist (NAN) and its team of dedicated officers whose constant encouragement, technical inputs and words of advice during the product development stage has ensured that this project has seen the light of the day.